Thermo Fisher Scientific opened a 300,000-sf viral vector center in August of 2022 in Plainville, Mass. Accelerating the creation of advanced cell and gene therapies, the cGMP-compliant facility offers flexible laboratories and production suites for the development, testing, and manufacture of viral vectors. Featuring Thermo Fisher’s advanced bioprocessing technologies and analytical instrumentation, the sustainably designed structure also includes sophisticated office environments and adjacent warehouse spaces. The project is part of an investment strategy to provide customers with fully integrated capabilities that connect the entire cell and gene therapy value chain from early development and clinical scale-up to commercial manufacturing.
